指南与共识慢性静脉疾病静脉血栓栓塞

支持髂静脉支架置入国际临床实践指南的文献综述及其在澳大利亚和新西兰实践的适用性

Review of the literature supporting international clinical practice guidelines on iliac venous stenting and their applicability to Australia and New Zealand practice.
指南 / 共识 · J Vasc Surg Venous Lymphat Disord · 2024-02-03

来自澳大利亚和新西兰的血管外科医生组成小组,通过问卷调查评估当地实践,并综述血管外科学会、美国静脉论坛、欧洲血管外科学会、美国静脉与淋巴学会、欧洲心血管与介入放射学会及美国心脏协会发布的慢性静脉疾病管理共识指南,与调查共识比较以评估在澳新实践的适用性,最终就患者选择和技术要点给出推荐。

要点

  • 有临床相关静脉流出道梗阻且CEAP评分≥3或静脉临床严重程度评分疼痛≥2分、影像显示狭窄>50%者,可考虑静脉支架置入(推荐等级Ib)。
  • 慢性盆腔痛、深部性交痛、影响生活质量的性交后疼痛且排除其他原因者,可考虑静脉支架置入(推荐等级Ic)。
  • 无症状患者不应提供静脉支架置入(推荐等级IIIc);急性髂股深静脉血栓清除术中发现>50%狭窄病变者,可考虑支架置入(推荐等级Ib)。

核心结论

  • 静脉流出道梗阻患者数十年来诊断不足和治疗不足,近年医生和业界的兴趣显著增加。
  • 旨在制定照护标准以避免治疗不足和过度治疗的国际指南适用于澳大利亚和新西兰实践,并将作为未来发展的教育平台。

研究设计与样本

  • 来自澳大利亚和新西兰、对静脉流出道梗阻管理有特定兴趣、培训和经验的血管外科医生组成小组,接受问卷调查以评估当前当地实践。
  • 分析调查结果并识别分歧领域后,小组对主要国际组织发布的慢性静脉疾病管理共识指南进行文献综述,并与调查共识比较。
  • 补充讨论选定的静脉支架置入关键研究、综述和荟萃分析;对一致性>75%的声明进行投票,识别指南适用性障碍;最终推荐由另一组静脉专家进一步审阅和认可。

主要发现

  • 文件涉及患者选择和技术方面两个关键领域。
  • 患者选择方面:有临床相关静脉流出道梗阻、临床-病因-解剖-病理生理评分≥3或静脉临床严重程度评分疼痛≥2分(或两者兼有),包括静脉性跛行,并有>50%狭窄证据者,可考虑静脉支架置入(推荐等级Ib)。
  • 慢性盆腔痛、深部性交痛、影响生活质量的性交后疼痛,在排除其他原因后,也可考虑静脉支架置入(推荐等级Ic)。
  • 无症状患者不应提供静脉支架置入(推荐等级IIIc)。
  • 因急性髂股深静脉血栓行血栓清除术、发现>50%狭窄病变者,可考虑静脉支架置入(推荐等级Ib)。

关键数值与推荐

  • 临床相关静脉流出道梗阻且CEAP评分≥3或VCSS疼痛≥2分(或两者兼有),包括静脉性跛行,影像显示>50%狭窄:可考虑静脉支架置入(推荐等级Ib)。
  • 慢性盆腔痛、深部性交痛、影响生活质量的性交后疼痛且排除其他原因:可考虑静脉支架置入(推荐等级Ic)。
  • 无症状患者:不应提供静脉支架置入(推荐等级IIIc)。
  • 急性髂股深静脉血栓血栓清除术中发现的>50%狭窄病变:可考虑静脉支架置入(推荐等级Ib)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The overall goal of this report is to provide a high-level, practical approach to managing venous outflow obstruction (VOO). METHODS: A group of vascular surgeons from Australia and New Zealand with specific interest, training, and experience in the management of VOO were surveyed to assess current local practices. The results were analyzed and areas of disagreement identified. After this, the group performed a literature review of consensus guidelines published by leading international organizations focused on the management of chronic venous disease, namely, the Society for Vascular Surgery, American Venous Forum, European Society for Vascular Surgery, American Vein and Lymphatic Society, Cardiovascular and Interventional Radiology Society of Europe, and American Heart Association. These guidelines were compared against the consensus statements obtained through the surveys to determine how they relate to Australian and New Zealand practice. In addition, selected key studies, reviews, and meta-analyses on venous stenting were discussed and added to the document. A selection of statements with >75% agreement was voted on, and barriers to the guideline's applicability were identified. The final recommendations were further reviewed and endorsed by another group of venous experts. RESULTS: The document addresses two key areas: patient selection and technical aspects of venous stenting. Regarding patient selection, patients with clinically relevant VOO, a Clinical-Etiologic-Anatomic-Physiologic score of ≥3 or a Venous Clinical Severity Score for pain of ≥2, or both, including venous claudication, with evidence of >50% stenosis should be considered for venous stenting (Level of Recommendation Ib). Patients with chronic pelvic pain, deep dyspareunia, postcoital pain affecting their quality of life, when other causes have been ruled out, should also be considered for venous stenting (Level of Recommendation Ic). Asymptomatic patients should not be offered venous stenting (Level of Recommendation IIIc). Patients undergoing thrombus removal for acute iliofemoral deep vein thrombosis, in whom a culprit stenotic lesion of >50% has been uncovered, should be considered for venous stenting (Level of Recommendation Ib). CONCLUSIONS: Patients with VOO have been underdiagnosed and undertreated for decades; however, in recent years, interest from physicians and industry has grown substantially. International guidelines aimed at developing standards of care to avoid undertreating and overtreating patients are applicable to Australia and New Zealand practice and will serve as an educational platform for future developments.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Villalba LM, Bayat I, Dubenec S, et al. Review of the literature supporting international clinical practice guidelines on iliac venous stenting and their applicability to Australia and New Zealand practice. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38316289. doi:10.1016/j.jvsv.2024.101843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。